Parameter

Relative difference*
(90% confidence interval)

4-Period crossover analysis of variance of log-transformed data

Low-fat meal

Medium-fat meal

High-fat meal

Effect

P-value

Cmax (ng/ml)†

109%
(101.1%-117.2%)

106%
(98.6%-114.5%)

116%
(107.8%-125.05%)

Sequence
Treatment
Period

0.077
0.013
0.860

AUC (ng*h/ml)‡

99%
(90.9%-108.3%)

105%
(96.4%-114.9%)

96%
(88.2%-105.1%)

Sequence
Treatment
Period

0.282
0.411
0.354

AUCT (ng*h/ml)‡

99%
(91.1%-108.6%)

105%
(95.9%-114.4%)

97%
(88.5%-105.6%)

Sequence
Treatment
Period

0.228
0.512
0.370
AUC: Area Under the Plasma Concentration-Versus-Time Curve;
AUCT: AUC to the Last Quantifiable Concentration at Time T;
Cmax: Peak Plasma Concentration.
*Relative difference in log-transformed geometric means for fed condition relative to fasting condition.+
†One subject in the low-fat treatment group was excluded.
‡One subject in the low-fat treatment group and one subject in the fasting treatment group were excluded.
Table 2: Statistical Comparisons of Pharmacokinetic Parameters Following a Single, Oral, 200 mg Dose of Desvenlafaxine Administered Under Fed Dosing Conditions Relative to Fasting Condition.
Goto home»